|
1
|
Kepil N, Batur S and Goksel S:
Immunohistochemical and genetic features of mucinous and
signet-ring cell carcinomas of the stomach, colon and rectum: A
comparative study. Int J Clin Exp Pathol. 12:3483–3491.
2019.PubMed/NCBI
|
|
2
|
Katada T, Ishiguro H, Kuwabara Y, Kimura
M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA
expression profile in undifferentiated gastric cancer. Int J Oncol.
34:537–542. 2009.PubMed/NCBI
|
|
3
|
Adachi Y, Yasuda K, Inomata M, Sato K,
Shiraishi N and Kitano S: Pathology and prognosis of gastric
carcinoma: Well versus poorly differentiated type. Cancer.
89:1418–1424. 2000.PubMed/NCBI
|
|
4
|
Noda S, Soejima K and Inokuchi K:
Clinicopathological analysis of the intestinal type and diffuse
type of gastric carcinoma. Jpn J Surg. 10:277–283. 1980.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Henson DE, Dittus C, Younes M, Nguyen H
and Albores-Saavedra J: Differential trends in the intestinal and
diffuse types of gastric carcinoma in the United States, 1973-2000:
Increase in the signet ring cell type. Arch Pathol Lab Med.
128:765–770. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nakamura T, Yao T, Niho Y and Tsuneyoshi
M: A clinicopathological study in young patients with gastric
carcinoma. J Surg Oncol. 71:214–219. 1999.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pozos-Ochoa LI, Lino-Silva LS,
León-Takahashi AM and Salcedo-Hernández RA: Prognosis of signet
ring cell carcinoma of the colon and rectum and their distinction
of mucinous adenocarcinoma with signet ring cells. A comparative
study. Pathol Oncol Res. 24:609–616. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hyngstrom JR, Hu CY, Xing Y, You YN, Feig
BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN and Chang GJ:
Clinicopathology and outcomes for mucinous and signet ring
colorectal adenocarcinoma: Analysis from the national cancer data
base. Ann Surg Oncol. 19:2814–2821. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nolte RT, Wisely GB, Westin S, Cobb JE,
Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK and
Milburn MV: Ligand binding and co-activator assembly of the
peroxisome proliferator-activated receptor-gamma. Nature.
395:137–143. 1998.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei
S, Mei S, Falck JR and Capdevila JH: Peroxisomal
proliferator-activated receptor-alpha-dependent inhibition of
endothelial cell proliferation and tumorigenesis. J Biol Chem.
282:17685–17695. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yokoyama Y, Xin B, Shigeto T, Umemoto M,
Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F and Mizunuma
H: Clofibric acid, a peroxisome proliferator-activated receptor
alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer
Ther. 6:1379–1386. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ramanan S, Kooshki M, Zhao W, Hsu FC and
Robbins ME: PPARalpha ligands inhibit radiation-induced microglial
inflammatory responses by negatively regulating NF-kappaB and AP-1
pathways. Free Radic Biol Med. 45:1695–1704. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang CY, Chao YJ, Chen YL, Wang TW, Phan
NN, Hsu HP, Shan YS and Lai MD: Upregulation of peroxisome
proliferator-activated receptor-α and the lipid metabolism pathway
promotes carcinogenesis of ampullary cancer. Int J Med Sci.
18:256–269. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Grygiel-Górniak B: Peroxisome
proliferator-activated receptors and their ligands: Nutritional and
clinical implications-a review. Nutr J. 13(17)2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pandey MK, Gupta SC, Nabavizadeh A and
Aggarwal BB: Regulation of cell signaling pathways by dietary
agents for cancer prevention and treatment. Semin Cancer Biol.
46:158–181. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu YL, Lin LC, Tung YT, Ho ST, Chen YL,
Lin CC and Wu JH: Rhododendron oldhamii leaf extract
improves fatty liver syndrome by increasing lipid oxidation and
decreasing the lipogenesis pathway in mice. Int J Med Sci.
14:862–870. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kliewer SA, Forman BM, Blumberg B, Ong ES,
Borgmeyer U, Mangelsdorf DJ, Umesono K and Evans RM: Differential
expression and activation of a family of murine peroxisome
proliferator-activated receptors. Proc Natl Acad Sci USA.
91:7355–7359. 1994.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Japanese Gastric Cancer Association:
Japanese Classification of Gastric Carcinoma. 15th ed. Tokyo,
Kanehara Shuppan, 2017 (In Japanese).
|
|
19
|
Tokuhara Y, Morinishi T, Matsunaga T,
Ohsaki H, Kushida Y, Haba R and Hirakawa E: Claudin-1, but not
claudin-4, exhibits differential expression patterns between well-
to moderately-differentiated and poorly-differentiated gastric
adenocarcinoma. Oncol Lett. 10:93–98. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lin MS, Huang JX, Chen WC, Zhang BF, Fang
J, Zhou Q, Hu Y and Gao HJ: Expression of PPARγ and PTEN in human
colorectal cancer: An immunohistochemical study using tissue
microarray methodology. Oncol Lett. 2:1219–1224. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dicken BJ, Bigam DL, Cass C, Mackey JR,
Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and
considerations for future directions. Ann Surg. 241:27–39.
2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu X, Cai H, Sheng W, Yu L, Long Z, Shi Y
and Wang Y: Clinicopathological characteristics and survival
outcomes of primary signet ring cell carcinoma in the stomach:
Retrospective analysis of single center database. PLoS One.
10(e0144420)2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pernot S, Voron T, Perkins G,
Lagorce-Pages C, Berger A and Taieb J: Signet-ring cell carcinoma
of the stomach: Impact on prognosis and specific therapeutic
challenge. World J Gastroenterol. 21:11428–11438. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jinawath N, Furukawa Y, Hasegawa S, Li M,
Tsunoda T, Satoh S, Yamaguchi T, Imamura H, Inoue M, Shiozaki H and
Nakamura Y: Comparison of gene-expression profiles between diffuse-
and intestinal-type gastric cancers using a genome-wide cDNA
microarray. Oncogene. 23:6830–6844. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sipponen P: Gastric cancer: Pathogenesis,
risks, and prevention. J Gastroenterol. 37 (Suppl 13):S39–S44.
2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hwang CS, Ahn S, Lee BE, Lee SJ, Kim A,
Choi CI, Kim DH, Jeon TY, Kim GH, Song GA and Park DY: Risk of
lymph node metastasis in mixed-type early gastric cancer determined
by the extent of the poorly differentiated component. World J
Gastroenterol. 22:4020–4026. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chirieac LR, Swisher SG, Correa AM, Ajani
JA, Komaki RR, Rashid A, Hamilton SR and Wu TT: Signet-ring cell or
mucinous histology after preoperative chemoradiation and survival
in patients with esophageal or esophagogastric junction
adenocarcinoma. Clin Cancer Res. 11:2229–2236. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Maggiora M, Oraldi M, Muzio G and Canuto
RA: Involvement of PPARα and PPARγ in apoptosis and proliferation
of human hepatocarcinoma HepG2 cells. Cell Biochem Funct.
28:571–577. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Zhang N, Chu ES, Zhang J, Li X, Liang Q,
Chen J, Chen M, Teoh N, Farrell G, Sung JJ and Yu J: Peroxisome
proliferator activated receptor alpha inhibits hepatocarcinogenesis
through mediating NF-κB signaling pathway. Oncotarget. 5:8330–8340.
2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
You BJ, Hour MJ, Chen LY, Luo SC, Hsu PH
and Lee HZ: Fenofibrate induces human hepatoma Hep3B cells
apoptosis and necroptosis through inhibition of thioesterase domain
of fatty acid synthase. Sci Rep. 9(3306)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gao J, Liu Q, Xu Y, Gong X, Zhang R, Zhou
C, Su Z, Jin J, Shi H, Shi J and Hou Y: PPARα induces cell
apoptosis by destructing Bcl2. Oncotarget. 6:44635–44642.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Morinishi T, Tokuhara Y, Ohsaki H, Ibuki
E, Kadota K and Hirakawa E: Activation and expression of peroxisome
proliferator-activated receptor alpha are associated with
tumorigenesis in colorectal carcinoma. PPAR Res.
2019(7486727)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Knapp P, Chabowski A, Błachnio-Zabielska
A, Jarząbek K and Wołczyński S: Altered peroxisome-proliferator
activated receptors expression in human endometrial cancer. PPAR
Res. 2012(471524)2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Luo Y, Chen L, Wang G, Qian G, Liu X, Xiao
Y, Wang X and Qian K: PPARα gene is a diagnostic and prognostic
biomarker in clear cell renal cell carcinoma by integrated
bioinformatics analysis. J Cancer. 10:2319–2331. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yu H and Xin Y: Down-regulated expressions
of PPARγ and its coactivator PGC-1 are related to gastric
carcinogenesis and Lauren's classification in gastric carcinoma.
Chin J Cancer Res. 25:704–714. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Theocharis S, Kanelli H, Politi E, Margeli
A, Karkandaris C, Philippides T and Koutselinis A: Expression of
peroxisome proliferator activated receptor-gamma in non-small cell
lung carcinoma: Correlation with histological type and grade. Lung
Cancer. 36:249–255. 2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Nomura S, Nakajima A, Ishimine S,
Matsuhashi N, Kadowaki T and Kaminishi M: Differential expression
of peroxisome proliferator-activated receptor in histologically
different human gastric cancer tissues. J Exp Clin Cancer Res.
25:443–448. 2006.PubMed/NCBI
|
|
38
|
Tan Y, Wang M, Yang K, Chi T, Liao Z and
Wei P: PPAR-α modulators as current and potential cancer
treatments. Front Oncol. 11(599995)2021.PubMed/NCBI View Article : Google Scholar
|
